ArticleAmerican journal of translational research2022
Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function and inflammatory factor levels in elderly patients with coronary heart disease.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Combined use of clopidogrel and atorvastatin for angina pectoris caused by coronary heart disease: clinical effectiveness, safety, and contributing factors.American journal of translational research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function, and inflammatory factor levels in elderly patients with coronary heart disease (CHD).
methodsA total of 100 elderly patients with CHD treated in our hospital from January 2018 to January 2020 were retrospectively selected and assigned to the control group (n=50) and the observation group (n=50) according to different types of medications. The control group was treated with clopidogrel bisulfate, while the observation group was treated with clopidogrel bisulfate combined with rosuvastatin. T
resultsThe clinical efficacy of the observation group was superior to the control group (P<0.05). No significant differences were determined in the levels of TC and LDL-C at T
conclusionRosuvastatin combined with clopidogrel bisulfate is effective in the treatment of elderly patients with CHD, which can effectively improve the cardiac function of patients and reduce the levels of blood lipids and inflammatory factors.
Indexed as
Identifiers
35273731PMC8902559W4226416252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.